WO2009089062A8 - Antagonistes de cadhérine-11 et procédés de traitement de troubles inflammatoires des articulations - Google Patents
Antagonistes de cadhérine-11 et procédés de traitement de troubles inflammatoires des articulations Download PDFInfo
- Publication number
- WO2009089062A8 WO2009089062A8 PCT/US2009/000162 US2009000162W WO2009089062A8 WO 2009089062 A8 WO2009089062 A8 WO 2009089062A8 US 2009000162 W US2009000162 W US 2009000162W WO 2009089062 A8 WO2009089062 A8 WO 2009089062A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cadherin
- treating inflammatory
- inflammatory joint
- joint disorders
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09700394.1T ES2611102T3 (es) | 2008-01-11 | 2009-01-09 | Anticuerpos con dominio EC1 dirigidos contra cadherina-11 para tratar trastornos inflamatorios articulares |
JP2010542284A JP5511684B2 (ja) | 2008-01-11 | 2009-01-09 | 炎症性関節障害を治療するためのカドヘリン−11eclドメインアンタゴニスト |
US12/811,921 US8591888B2 (en) | 2008-01-11 | 2009-01-09 | Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders |
SI200931574T SI2242769T1 (sl) | 2008-01-11 | 2009-01-09 | Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov |
EP09700394.1A EP2242769B1 (fr) | 2008-01-11 | 2009-01-09 | Anticorps anti-cadhérine-11 ec1 et procédés de traitement de troubles inflammatoires des articulations |
MX2010007551A MX2010007551A (es) | 2008-01-11 | 2009-01-09 | Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion. |
CN200980101955.3A CN101952316B (zh) | 2008-01-11 | 2009-01-09 | 用于治疗炎性关节障碍的钙黏着蛋白-11 ec1结构域拮抗剂 |
AU2009204467A AU2009204467B2 (en) | 2008-01-11 | 2009-01-09 | Cadherin-11 ECl domain antagonists for treating inflammatory joint disorders |
CA2711394A CA2711394A1 (fr) | 2008-01-11 | 2009-01-09 | Antagonistes de cadherine-11 et procedes de traitement de troubles inflammatoires des articulations |
DK09700394.1T DK2242769T3 (en) | 2008-01-11 | 2009-01-09 | ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATMENT OF INFLAMMATORY LED DISEASES |
BRPI0906492A BRPI0906492A2 (pt) | 2008-01-11 | 2009-01-09 | antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações |
US12/427,993 US7972846B2 (en) | 2008-01-11 | 2009-04-22 | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
IL206880A IL206880A (en) | 2008-01-11 | 2010-07-08 | An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody |
US12/837,110 US20110045003A1 (en) | 2008-01-11 | 2010-07-15 | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
US14/070,106 US9315568B2 (en) | 2008-01-11 | 2013-11-01 | Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1073408P | 2008-01-11 | 2008-01-11 | |
US61/010,734 | 2008-01-11 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/811,921 A-371-Of-International US8591888B2 (en) | 2008-01-11 | 2009-01-09 | Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders |
US12/427,993 Continuation-In-Part US7972846B2 (en) | 2008-01-11 | 2009-04-22 | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
US14/070,106 Continuation US9315568B2 (en) | 2008-01-11 | 2013-11-01 | Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009089062A2 WO2009089062A2 (fr) | 2009-07-16 |
WO2009089062A3 WO2009089062A3 (fr) | 2009-09-24 |
WO2009089062A8 true WO2009089062A8 (fr) | 2010-09-02 |
Family
ID=40602259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/000162 WO2009089062A2 (fr) | 2008-01-11 | 2009-01-09 | Antagonistes de cadhérine-11 et procédés de traitement de troubles inflammatoires des articulations |
Country Status (15)
Country | Link |
---|---|
US (4) | US8591888B2 (fr) |
EP (2) | EP3181588A1 (fr) |
JP (1) | JP5511684B2 (fr) |
CN (1) | CN101952316B (fr) |
AU (1) | AU2009204467B2 (fr) |
BR (1) | BRPI0906492A2 (fr) |
CA (1) | CA2711394A1 (fr) |
DK (1) | DK2242769T3 (fr) |
ES (1) | ES2611102T3 (fr) |
HU (1) | HUE031207T2 (fr) |
IL (1) | IL206880A (fr) |
MX (1) | MX2010007551A (fr) |
PL (1) | PL2242769T3 (fr) |
SI (1) | SI2242769T1 (fr) |
WO (1) | WO2009089062A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3181588A1 (fr) | 2008-01-11 | 2017-06-21 | Adheron Therapeutics, Inc. | Antagonistes cadherin-11 et procédés de traitement de troubles inflammatoires des articulations |
US8877188B2 (en) | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
JP5911848B2 (ja) * | 2010-05-04 | 2016-04-27 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 線維症の検出および処置 |
BR112013001062A2 (pt) * | 2010-07-15 | 2016-05-24 | Synovex Corp | anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados |
WO2013130767A1 (fr) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Poudres sèches pouvant être inhalées |
KR20130142025A (ko) * | 2012-06-18 | 2013-12-27 | 한국생명공학연구원 | 카드헤린―11 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물 |
US11097005B2 (en) | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
WO2016196146A1 (fr) | 2015-05-29 | 2016-12-08 | Children's Hospital Medical Center | Agents thérapeutiques à base de cdh26 et leur utilisation |
KR101654526B1 (ko) * | 2015-10-19 | 2016-09-06 | 한국생명공학연구원 | 카드헤린―11 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물 |
EP4059570A1 (fr) | 2016-01-13 | 2022-09-21 | Children's Hospital Medical Center | Compositions et méthodes de traitement d'états inflammatoires allergiques |
US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US248220A (en) * | 1881-10-11 | Machine for graining and dicing leather | ||
US229811A (en) * | 1880-07-13 | dtjnlop | ||
US253200A (en) * | 1882-02-07 | Timothy guilford | ||
US110755A (en) * | 1871-01-03 | Improvement in spike-machines | ||
US248219A (en) * | 1881-10-11 | Panorama-toy | ||
US215482A (en) * | 1879-05-20 | Improvement in spring be d-bottoms | ||
US8323A (en) * | 1851-08-26 | colne | ||
US96746A (en) * | 1869-11-09 | Improvement in mechanical movements | ||
US229199A (en) * | 1880-06-22 | Wood-working machine | ||
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
EP0232262A4 (fr) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | Microorganisme producteur de tryptophane. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0533838T3 (da) | 1990-06-11 | 1998-02-23 | Nexstar Pharmaceuticals Inc | Nukleinsyreligander |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
DE59109032D1 (de) | 1990-06-28 | 1998-09-03 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
CU22584A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
US5859136A (en) * | 1997-11-03 | 1999-01-12 | E. I. Du Pont De Nemours And Company | Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent |
US6638911B1 (en) | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
CA2327530A1 (fr) | 1998-05-05 | 1999-11-11 | Adherex Technologies, Inc. | Composes et procedes servant a moduler des fonctions etablies par l'intermediaire de cadherine non classique |
US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
EP1207905B1 (fr) | 1999-09-03 | 2010-09-01 | The Brigham And Women's Hospital, Inc. | Techniques et compositions destinees au traitement de maladie inflammatoire par utilisation d'agents de modulation cadherine-11 |
US6787136B1 (en) * | 1999-09-03 | 2004-09-07 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
US20040110755A1 (en) * | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
AU2003298475A1 (en) * | 2002-11-14 | 2004-06-18 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
US6952969B2 (en) * | 2003-09-30 | 2005-10-11 | The Aerospace Corporation | Ceramic ball bearing fracture test method |
EP1853255A4 (fr) * | 2005-02-22 | 2009-07-08 | Gemin X Pharmaceuticals Canada | Procédés pour traiter l arthrite à l aide de composés trihétérocycliques |
EP3181588A1 (fr) | 2008-01-11 | 2017-06-21 | Adheron Therapeutics, Inc. | Antagonistes cadherin-11 et procédés de traitement de troubles inflammatoires des articulations |
WO2009101059A2 (fr) | 2008-02-11 | 2009-08-20 | Novartis Ag | Procédés d'utilisation d'antagonistes de la cadhérine 11 (cdh11) |
CA2760642A1 (fr) * | 2009-05-01 | 2010-11-04 | The University Of Tokyo | Anticorps anti-cadherine |
BR112013001062A2 (pt) | 2010-07-15 | 2016-05-24 | Synovex Corp | anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados |
-
2009
- 2009-01-09 EP EP16194905.2A patent/EP3181588A1/fr not_active Withdrawn
- 2009-01-09 ES ES09700394.1T patent/ES2611102T3/es active Active
- 2009-01-09 JP JP2010542284A patent/JP5511684B2/ja active Active
- 2009-01-09 EP EP09700394.1A patent/EP2242769B1/fr active Active
- 2009-01-09 CN CN200980101955.3A patent/CN101952316B/zh active Active
- 2009-01-09 US US12/811,921 patent/US8591888B2/en active Active
- 2009-01-09 MX MX2010007551A patent/MX2010007551A/es active IP Right Grant
- 2009-01-09 PL PL09700394T patent/PL2242769T3/pl unknown
- 2009-01-09 HU HUE09700394A patent/HUE031207T2/hu unknown
- 2009-01-09 CA CA2711394A patent/CA2711394A1/fr not_active Abandoned
- 2009-01-09 AU AU2009204467A patent/AU2009204467B2/en not_active Ceased
- 2009-01-09 SI SI200931574T patent/SI2242769T1/sl unknown
- 2009-01-09 DK DK09700394.1T patent/DK2242769T3/en active
- 2009-01-09 WO PCT/US2009/000162 patent/WO2009089062A2/fr active Application Filing
- 2009-01-09 BR BRPI0906492A patent/BRPI0906492A2/pt not_active IP Right Cessation
- 2009-04-22 US US12/427,993 patent/US7972846B2/en active Active
-
2010
- 2010-07-08 IL IL206880A patent/IL206880A/en not_active IP Right Cessation
- 2010-07-15 US US12/837,110 patent/US20110045003A1/en not_active Abandoned
-
2013
- 2013-11-01 US US14/070,106 patent/US9315568B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE031207T2 (hu) | 2017-07-28 |
EP2242769B1 (fr) | 2016-11-02 |
AU2009204467A1 (en) | 2009-07-16 |
AU2009204467B2 (en) | 2012-09-06 |
US8591888B2 (en) | 2013-11-26 |
US20090253200A1 (en) | 2009-10-08 |
DK2242769T3 (en) | 2017-02-06 |
JP5511684B2 (ja) | 2014-06-04 |
CN101952316B (zh) | 2015-04-01 |
SI2242769T1 (sl) | 2017-02-28 |
CN101952316A (zh) | 2011-01-19 |
IL206880A (en) | 2014-12-31 |
PL2242769T3 (pl) | 2017-06-30 |
US7972846B2 (en) | 2011-07-05 |
WO2009089062A3 (fr) | 2009-09-24 |
WO2009089062A2 (fr) | 2009-07-16 |
ES2611102T3 (es) | 2017-05-04 |
US20110045003A1 (en) | 2011-02-24 |
US9315568B2 (en) | 2016-04-19 |
EP3181588A1 (fr) | 2017-06-21 |
EP2242769A2 (fr) | 2010-10-27 |
US20140120104A1 (en) | 2014-05-01 |
IL206880A0 (en) | 2010-12-30 |
US20110008323A1 (en) | 2011-01-13 |
CA2711394A1 (fr) | 2009-07-16 |
MX2010007551A (es) | 2010-11-30 |
BRPI0906492A2 (pt) | 2015-12-01 |
JP2011509094A (ja) | 2011-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009089062A8 (fr) | Antagonistes de cadhérine-11 et procédés de traitement de troubles inflammatoires des articulations | |
WO2010008831A3 (fr) | Composés et procédés pour moduler les récepteurs couplés à la protéine g | |
EP3345925A3 (fr) | Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés | |
IL243574B (en) | A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors | |
AU2011234398A8 (en) | Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
TN2011000171A1 (en) | Isonicotinamide orexin receptor antagonists | |
WO2012075383A3 (fr) | Inhibiteurs de bromodomaines et leurs utilisations | |
HK1134084A1 (en) | Pyridyl piperidine orexin receptor antagonists | |
WO2012174487A3 (fr) | Inhibiteurs à bromodomaine et leurs utilisations | |
WO2012151512A3 (fr) | Inhibiteurs de bromodomaines et leurs utilisations | |
MX361542B (es) | Compuestos de morfinan. | |
WO2009082038A3 (fr) | Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie | |
WO2007081792A3 (fr) | Procedes et compositions associees pour l'amelioration de proprietes d'agents pharmacologiques ciblant le systeme nerveux | |
WO2009023539A3 (fr) | Dérivés amides utilisés comme antagonistes des trpv1 | |
UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
WO2010115751A3 (fr) | Dérivés d'oxadiazole | |
TN2011000282A1 (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
WO2010017368A3 (fr) | Méthodes et compositions pour traiter l’anxiété | |
WO2010085820A3 (fr) | Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine | |
MX350862B (es) | Acidos de piperidinil naftilacetico. | |
WO2010077976A3 (fr) | Antagoniste du récepteur de la prokinéticine et ses utilisations | |
EA201100013A1 (ru) | Фармацевтические композиции на основе антагонистов кининового рецептора b2 и кортикостероидов и их применение | |
WO2008101219A3 (fr) | Compositions et procédés d'inhibition ou d'inversion de troubles fibrotiques | |
WO2012048243A3 (fr) | Agents thérapeutiques pour trouble dépressif avec des analogues de créatine | |
WO2009108635A3 (fr) | Nouvelles compositions et méthodes de traitement de maladies associées aux lymphocytes activés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980101955.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09700394 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2711394 Country of ref document: CA Ref document number: 2009204467 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010542284 Country of ref document: JP Ref document number: 206880 Country of ref document: IL Ref document number: MX/A/2010/007551 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009204467 Country of ref document: AU Date of ref document: 20090109 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009700394 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009700394 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12811921 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0906492 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100712 |